Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China

ObjectiveSix anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs), including one domestic (ensartinib) and five imported ALK-TKIs (crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib), have been recommended as first-line treatments for advanced ALK-positive NSCLC in China. This...

Full description

Bibliographic Details
Main Authors: Xia Luo, Zhen Zhou, Xiaohui Zeng, Liubao Peng, Qiao Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Public Health
Subjects:
cost-effectiveness
Non-small cell lung cancer
ALK-TKI
ensartinib
domestic anticancer drug
China
Online Access:https://www.frontiersin.org/articles/10.3389/fpubh.2022.985834/full

Internet

https://www.frontiersin.org/articles/10.3389/fpubh.2022.985834/full

Similar Items